COBRE: WVU: SIGNAL TRANSDUCTION & CANCER: MASS SPECTROMETRY & PROTEOMICS CORE

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The WVU Proteomics Core Facility was established in 2001 as part of the COBRE grant, and is currently offering MALDI-TOF-MS and LC-MS/MS protein identification and 2-D gel protein separations and analysis as a service to WVU and neighboring institutions. This core will serve five functions: 1) Differential expression analysis or the identification and relative quantification of up- and down-regulated proteins between two different samples (health versus diseased). 2) Functional protein analysis, which will isolate and identify proteins associated in complexes. 3) Protein identification, which will identify proteins isolated by gel electrophoresis, western blotting or chromatography. 4) Micro-characterization, which will identify and map post-translational modifications of proteins. 5) Structural analysis, which will use the distance constraints for determination of a proteins three-dimensional structure. This final capability involves cross-linking proteins at specific functional groups, proteolytic digestion, and MS analysis. MS analysis of cross-linked peptides provides information on proximity of these peptides in three-dimensional structure. Embodied in the first function can be the determination of the proteomic complement of a cell, tissue or biological fluid. This renewal application describes: 1) the Facilitys history, current instrumentation, and personnel, 2) the Core Facility Operational Plan, 3) the role of the Core Facility in fulfilling research objectives in COBRE-funded and other research programs at WVU, 4) research projects in Signal Transduction and Cancer that will be supported by the Core Facility in the next funding cycle of the COBRE grant, and 5) progress on efforts to obtain additional funding for the Facility.